

Event at-a-glance
The EVIDENCE 360: RWE, Pricing & Reimbursement Summit USA, hosted by Veridon Global on 26th-27th June 2025 in Philadelphia, USA, is a groundbreaking two-day event dedicated to advancing the role of Real-World Evidence (RWE) in shaping healthcare policies and market access strategies. This summit is a convergence of healthcare professionals, pharmaceutical professionals, policymakers, researchers, and data scientists, united to address the most pressing challenges and opportunities in RWE, pricing strategies, and reimbursement frameworks in the U.S. context. Designed to facilitate in-depth knowledge sharing and collaborative problem-solving, the summit will spotlight innovative approaches for leveraging RWE to improve patient outcomes and optimize healthcare costs.
Discussions will cover critical topics such as harnessing AI, machine learning, and big data to revolutionize RWE analysis; overcoming disparities in the U.S. reimbursement landscape; incorporating Patient-Reported Outcomes (PROs) to drive patient-centric care; and adapting pricing models for precision medicine. Additionally, the event will delve into regulatory challenges, including FDA acceptance of RWE, and explore how RWE can be strategically utilized in Health Technology Assessments (HTAs). By providing actionable insights and fostering connections among industry leaders, this summit will serve as a catalyst for innovation in healthcare decision-making. Join us in Philadelphia to be part of this transformative conversation shaping the future of evidence-based.

Key Topics
- Bridging the gap between clinical trial data and real-world outcomes to improve healthcare access
- Using AI, machine learning, and big data to generate actionable insights from real-world datasets
- Leveraging Patient-Reported Outcomes (PROs) and patient-centric data to optimize access strategies
- Navigating Fragmented Reimbursement Policies in the U.S.
- Exploring differences between U.S. HTA practices and global approaches
- Aligning pricing and reimbursement strategies with evolving healthcare policies

Why join us?
- Gain insights into the latest RWE trends and how they influence pricing and reimbursement strategies in USA.
- Network with key industry leaders and regulators shaping the future of healthcare policy and market access.
- Learn about the role of RWE in regulatory decision-making and how it influences health technology assessments (HTAs).
- Explore the integration of AI and digital health in driving more efficient and effective reimbursement decisions.
- Collaborate on overcoming the key challenges in integrating RWE and enhancing patient outcomes through data-driven decisions.

Target Audience
- Pharmaceutical and Biotech Companies: Executives, decision-makers, and researchers involved in drug development, market access, and pricing strategies.
- Regulators and Policy Makers – Representatives from healthcare authorities, regulatory bodies, and health technology assessment (HTA) agencies across USA.
- Researchers– Experts using RWE to assess treatment outcomes, improve healthcare models, and support regulatory submissions.
- Advisors and Payers – Professionals providing guidance on pricing strategies, reimbursement, and RWE implementation.
- Investors – Individuals and firms interested in funding innovation in healthcare, particularly in RWE and value-based pricing models.

Speakers

Sunil Dravida

Pamela Landsman-Blumberg

Lin Wang

Charles Makin

Ravi Iyer

Sandipan Bhattacharjee

Sumati Rao

Amit Raval

Kunal Kaushal

Paresh Chaudhari

Boxiong Tang

Yash Jalundhwala
